Abstract 363P
Background
Lung cancer with family history have been increasing gradually of late years in East Asian, especially those presenting as pulmonary ground-glass nodules (GGNs). The genome predisposition of GGNs with lung cancer family history remains baffling.
Methods
This prospective study (NCT04220268) enrolled patients with pulmonary pre-invasive or invasive adenocarcinoma, which presenting as GGNs in computer tomography (CT) scans. We collected blood and tumor samples from 59 patients with GGNs and first-degree relative family history of lung cancer (FHLC) to investigated germline and somatic mutations by whole exome sequencing (WES). Pre-invasive neoplasia causal variants were detected by quality, classification, minor allele frequency (MAF), functional prediction, and family segregation filter. Validation was conducted in an external cohort of 669 healthy participants without cancer, and in 126 nonoverlapping susceptibility loci for lung carcinogenesis identified by recent genome-wide association studies (GWAS).
Results
Eighty-five single nucleotide variants (SNVs) and 11 frameshifts were detected, which were rare, predicted as damaging, and presented in more than two families. Fifteen of them had been reported that were associated with high risk of lung cancer or deleterious function. The MAF of them were lower than 0.01 in a local health Asian cohort and human exome databases. Three of them were validated in 126 susceptibility loci for lung carcinogenesis. The number of the rare, damaging and repeatedly germline mutations in non-smoking patients were significantly higher than those in smoking patients (2436 vs 593, p<0.05). The number of these germline mutation showed no significant difference between the patients with pure GGNs and mixed GGNs (1298 vs 1333, p>0.05).
Conclusions
Patients with GGNs and FHLC may have inheritable carcinogenesis mutations. These variants may potentially contribute to the risk of pulmonary pre-invasive adenocarcinoma susceptibility in Chinese population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine (Grant No. 2017B030314120), National Natural Science Foundation of China (Grant No. 81673031&No. 81872510), High-level Hospital Construction Project (DFJH201801), Guangdong Provincial People's Hospital Young Talent Project (No. GDPPHYTP201902).
Disclosure
R-R. Chen, Z-X. Tai, H-X. Lin: Full/Part-time employment: GenePlus-Beijing Institute, Beijing, China. All other authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session